Esperion Therapeutics, Inc., a prominent player in the health care biotechnology sector, is headquartered in Ann Arbor, United States. The company specializes in the development of oral and small molecule therapies aimed at treating patients with elevated levels of low-density lipoprotein cholesterol and other cardio metabolic risk factors. As a publicly traded entity, Esperion Therapeutics is listed on the Nasdaq under the ticker symbol ESPR.
As of the latest available data, Esperion Therapeutics has not issued any new announcements. The company’s stock performance over the past year has been characterized by a modest upward trend. On January 8, 2026, the closing price of Esperion Therapeutics’ shares was $3.88. This price point is indicative of a recovery from a significant low of $0.69, recorded on May 14, 2025. The stock reached a 52-week high of $4.18 on January 7, 2026, suggesting that the current trading levels are nearing this recent peak.
The volatility observed in Esperion Therapeutics’ stock price over the past year highlights a pattern of significant price fluctuations. Despite these swings, the overall trajectory of the stock has been bullish, maintaining a relatively narrow range compared to its historical extremes. This trend reflects investor confidence in the company’s potential and its strategic focus on addressing critical health care needs.
With a market capitalization of approximately $942.35 million USD, Esperion Therapeutics continues to be a noteworthy entity within the biotechnology industry. The company’s focus on innovative therapies for cardiovascular risk factors positions it as a key player in the ongoing efforts to improve patient outcomes in the health care sector. As the company progresses with its research and development initiatives, stakeholders will be closely monitoring its performance and strategic developments in the coming months.
